Cassava Sciences Halts Alzheimer's Drug Trials After Major Setback
Cassava Sciences' stock plummeted over 83% after its Alzheimer's drug, simufilam, failed to show significant improvement in patients during Phase 3 trials. This marks the stock's lowest point in over four years, as the treatment did not outperform a placebo in cognitive or functional decline among patients with mild-to-moderate Alzheimer's disease.